November 2, 2026Stocks·Bullish·regulatory
FDA grants RMAT designations to CTX310 for severe hypertriglyceridemia and elevated LDL cholesterol
CRISPR Therapeutics says the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL cholesterol.
Detected & updated continuously · Source: Nebula
Story subjects
CRISPR Therapeutics AGFood and Drug Administration